PT -期刊文章盟Arnaud布非盟-唐Husereau盟-尼古拉斯·莫伦纳盟Sarowar Golam AU -穆罕默德Kashif席迪圭盟莱安德罗林德纳AU -小许TI Matching-adjusted间接比较benralizumab < em >和< / em > interleukin-5抑制剂治疗严重的哮喘:系统回顾援助- 10.1183/13993003.01393 -2018 DP - 2018年11月01 TA -欧洲呼吸杂志》第六PG - 1801393 - 52 IP - 5 4099 - //www.qdcxjkg.com/content/52/5/1801393.short 4100 - //www.qdcxjkg.com/content/52/5/1801393.full所以欧元和J2018 11月01;52 AB - Benralizumab是interleukin-5受体α-directed溶细胞的单克隆抗体,直接耗尽嗜酸性粒细胞。其相对有效性与其他IL-5-targeted治疗患者严重,不受控制的哮喘是没有完全的特征。我们执行一个matching-adjusted间接比较(MAIC) benralizumab和mepolizumab reslizumab。试验选择通过系统回顾和评估的试验方法。Benralizumab患者的立场数据加权匹配treatment-effect-modifying病人的特点比较器试验之前间接效果比较。匹配的调整后,benralizumab和mepolizumab减少发作与安慰剂52%和49%,分别(率比(RR) 0.94, 95%可信区间0.78 - -1.13;n = 1524)和减少了需要住院治疗的急性加重率/急诊服务52%和52%,分别(相对危险度1.00,95%可信区间0.57 - -1.75;n = 1524)。Benralizumab和mepolizumab同样改善pre-bronchodilator用力呼气量在1 s 32周(差异0.03 L, 95% CI 0.06−-0.12;n = 1443)。Benralizumab和reslizumab患者群体太不同的生成足够的有效样本量为MAIC产生一个可靠的估计。MAIC是一个健壮的方式间接比较治疗药效试验和异构的患者群体。 When baseline patient characteristics were matched across asthma trials, benralizumab and mepolizumab yielded similar efficacy.In an indirect treatment comparison with matched populations, benralizumab and mepolizumab had comparable efficacy http://ow.ly/e5kC30md39F